恩替卡韦与富马酸丙酚替诺福韦片治疗对CHB患者病毒学应答及肝肾功能的疗效及安全性对比观察  

Comparison of the effects of entecavir and tenofovir alafenamide fumarate tablets on virological response and liver and kidney function in patients with CHB

作　　者：汤文芳 何树添 古飞翔 陈幸金 Tang Wen-fang;He Shu-tian;Gu Fei-xiang;Chen Xing-jin(Department of infectious diseases,Xunwu County People's Hospital,Ganzhou 342200,Jiangxi,China)

机构地区：[1]寻乌县人民医院感染性疾病科,江西赣州342200

出　　处：《四川生理科学杂志》2025年第3期673-675,共3页

摘　　要：目的:观察恩替卡韦(Entecavir,ETV)与富马酸丙酚替诺福韦片(Tenofovir alafenamide Fumarate tablets,TAF)对慢性乙型肝炎(Chronic hepatitis B,CHB)患者病毒学应答、肝肾功能及安全性的影响。方法:选取2021年1月至2024年4月本院就诊的CHB患者68例,随机分为对照组和观察组,每组34例。对照组接受ETV治疗,观察组接受TAF治疗,比较两组乙型肝脏病毒(Viral hepatitis type,HBV)脱氧核糖核酸(Deoxyribonucleic acid,DNA)水平和病毒学应答率、肝肾功能[丙氨酸转氨酶(Alanine aminotransferase,ALT)、天冬氨酸转氨酶(Aspartate transaminase,AST)、血肌酐(Serum creatinine,SCr)、肾小球滤过率(Estimated glomerular filtration rate,eGFR)]以及不良发应发生率。结果:治疗后观察组HBV DNA水平低于对照组(P<0.05),但两组病毒应答率比较无统计学意义;治疗后观察组ALT、AST水平低于对照组(P<0.05);治疗后两组SCr、eGFR水平比较无统计学意义;两组不良发应发生率比较无统计学意义。结论:采用TAF治疗CHB患者可降低其HBV DNA水平,提升抗病毒效果,并改善患者肝功能,安全性较高。Objective:To observe the effects of entecavir(ETV)and tenofovir alafenamide fumarate tablets(TAF)on virological response,liver and kidney function,and safety in patients with chronic hepatitis B(CHB).Methods:Sixty-eight patients with CHB admitted to the hospital from January 2021 to April 2024 were selected and divided into a control group and an observation group randomly,34 patients in each group.The former group was treated with ETV,and the latter group was treated with TAF.Hepatitis B virus(HBV)DNA level,virological response rate,liver and kidney function[alanine aminotransferase(ALT),aspartate aminotransferase(AST),serum creatinine(SCr)and glomerular filtration rate(eGFR)],and the incidence of adverse reactions were compared between the two groups.Results:After treatment,HBV DNA level in the observation group was lower compared to the control group(P<0.05),but there was no statistically significant difference in virological response rate between the groups.After treatment,the levels of ALT and AST in the observation group were lower compared to the control group(P<0.05).The two groups showed no statistically significant differences in SCr,eGFR and the incidence of adverse reactions.Conclusion:TAF treatment can lower HBV DNA levels in patients with CHB,enhance antiviral effect,and improve their liver function,with high safety.

关 键 词：慢性乙型肝炎 恩替卡韦 富马酸丙酚替诺福韦片 病毒学应答 肝肾功能 安全性 

分 类 号：R51[医药卫生—内科学]